Search by Drug Name or NDC
NDC 00074-2042-02 Skyrizi Details
Skyrizi
Skyrizi is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is .
MedlinePlus Drug Summary
Risankizumab-rzaa injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. Risankizumab-rzaa is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.
Related Packages: 00074-2042-02Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Risankizumab-rzaa Injection
Product Information
| NDC | 00074-2042 |
|---|---|
| Product ID | 0074-2042_05c4dbfd-4d63-4c5f-950b-cca935a753c3 |
| Associated GPIs | 9025057070F820 |
| GCN Sequence Number | 079673 |
| GCN Sequence Number Description | risankizumab-rzaa SYRINGE 75 MG/0.83 SUBCUT |
| HIC3 | L1A |
| HIC3 Description | ANTIPSORIATIC AGENTS,SYSTEMIC |
| GCN | 46213 |
| HICL Sequence Number | 045699 |
| HICL Sequence Number Description | RISANKIZUMAB-RZAA |
| Brand/Generic | Brand |
| Proprietary Name | Skyrizi |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Risankizumab-rzaa |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | KIT |
| Route | n/a |
| Active Ingredient Strength | n/a |
| Active Ingredient Units | n/a |
| Substance Name | n/a |
| Labeler Name | AbbVie Inc. |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761105 |
| Listing Certified Through | n/a |
Package
NDC 00074-2042-02 (00074204202)
| NDC Package Code | 0074-2042-02 |
|---|---|
| Billing NDC | 00074204202 |
| Package | 1 KIT in 1 CARTON (0074-2042-02) * 1 mL in 1 PACKET * .83 mL in 1 SYRINGE |
| Marketing Start Date | 2019-04-23 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |